| Pharmaceutical Products and Services | APIs (oncology/non-oncology), formulations, biosimilars, specialty chemicals, novel drug delivery systems | Strong R&D, regulatory expertise, diversified portfolio, global manufacturing network, patent protections | B2B clients including global pharmaceutical companies, healthcare providers, and distributors | Biosimilars, novel formulations, specialty CDMO services | 128278 | 99 | Product sales, licensing, contract development and manufacturing services | Direct sales, licensing fees, long-term CDMO contracts | Regulatory approvals, new product launches, capacity expansions, global partnerships | Noduca, Ibrushil, Lenshil, High Concentration Adalimumab |
| Power | Power generation facilities to support manufacturing units | Integrated power ensures cost control and operational stability | Company’s manufacturing units primarily | | 2 | 1 | Sale of power internally and possible surplus externally | Operational cost allocation | Increasing manufacturing capacity requiring reliable power supply | |
| Others | Miscellaneous income and services unrelated to core pharma businesses | | N/A | | 1 | 0 | Various smaller operations and investments | N/A | | |
